FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.

FDA’s ‘mixed signals’ on diversity have entangled clinical trials. Here’s how pharma can push ahead.

The agency is still unclear about where it will stand on clinical trial diversity, but companies are looking for answers and leaning toward good science.